Mallinckrodt (MNK) reported pre-market Friday results from a study which it said demonstrated the effectiveness of Extracorporeal Photopheresis (ECP) as an adjunct to standard therapy in lung transplant recipients with Bronchiolitis Obliterans Syndrome (BOS).

Findings of the study revealed that ECP significantly improves survival probability in double-lung transplant patients diagnosed with BOS compared to standard BOS-directed therapies alone. Survival probability was improved by approximately 30% in the ECP-treated patients who were observed for a period of up to 15.5 years as compared to matched controls, the company said.

The study also showed that the addition of ECP to standard therapy has a significant positive effect on the number of total re-admissions to the hospital, the total days of care and the total patient days, compared to treatment with standard therapy alone, according to the pharmaceutical firm.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.